Novo hemophila drug approved

Share this article:

The FDA approved Novo Nordisk's Hemophilia A drug Novoeight. The Danish drug maker said in a statement Wednesday that it expects to have the drug on the US market during 2015's second quarter.

The treatment is for a type of hemophilia that typically affects men, and is the result of a missing or malfunctioning factor VIII protein.

The drug was among an elite list of medications approved during the government's 16-day shutdown.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions